This research investigates polyploid giant cancer cells, a highly treatment-resistant population responsible for cancer relapse. By studying their structural biology and dependence on lipid metabolism, the work identifies metabolic vulnerabilities that can be targeted alongside chemotherapy, offering a promising strategy to eliminate resistant cancer cells and improve long-term treatment outcomes.

This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research develops gold nanoparticles coated with peptides to block DNA repair in colorectal cancer cells, helping overcome drug resistance. Laboratory studies show the treatment dramatically reduces cancer cell survival after radiation while minimising toxicity. The approach could provide a safer, more effective therapy for colorectal cancer and other drug-resistant cancers.

This research investigates how glutamine-rich regions within the LAG-3 protein influence Notch signaling, a critical pathway for cell communication and development. Using CRISPR gene editing, the study found that removing glutamine repeats alters stem cell behavior and cell-cycle progression, providing insights relevant to cancer, Alzheimer’s disease, and future therapies.

This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

This research uses artificial intelligence to predict the progression of Alzheimer’s disease and cancer using medical imaging data. By analyzing brain scans, tumor scans, and treatment responses, AI models can forecast disease development and treatment outcomes, enabling earlier intervention, more personalized care, and improved quality of life for aging populations.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

This research uses spatial transcriptomics to map interactions between T cells, cancer cells, and immunosuppressive cells in tumours. Findings suggest cancer suppresses immune responses by surrounding and weakening T cells. The work aims to improve immunotherapy and enable personalised cancer treatment through detailed tumour mapping.

This research investigates the protein SLX4, a key coordinator of DNA repair. Using complementary techniques, it identifies 221 interacting proteins, most previously unknown. Findings reveal a complex network involved in genome maintenance, offering new insights into cellular repair mechanisms and improving understanding of diseases such as cancer.